Evidence map›Paper›PMID 27192669›Full record

ArticleThe New England journal of medicine2016

Essential Medicines in the United States--Why Access Is Diminishing.

Jonathan D Alpern, John Song, William M Stauffer

Abstract read
PubMed Publisher
In one paragraph

Article in The New England journal of medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Bulletin of the World Health Organization · 2024
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Artesunate Versus Quinine: Keeping Our Options Open.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Trends in Pricing and Generic Competition Within the Oral Antibiotic Drug Market in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017
    Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Jonathan D AlpernFrom the Division of Infectious Diseases (J.D.A., W.M.S.) and the Center for Bioethics and Division of General Internal Medicine (J.S.), University of Minnesota, Minneapolis.
John SongFrom the Division of Infectious Diseases (J.D.A., W.M.S.) and the Center for Bioethics and Division of General Internal Medicine (J.S.), University of Minnesota, Minneapolis.
William M StaufferFrom the Division of Infectious Diseases (J.D.A., W.M.S.) and the Center for Bioethics and Division of General Internal Medicine (J.S.), University of Minnesota, Minneapolis.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Government RegulationDrug CompoundingDrug CostsDrug IndustryDrugs, EssentialEconomic CompetitionHumansPrivate SectorUnited StatesWorld Health OrganizationDrugs, Essential

Identifiers

PMID27192669

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.